natgillin/translations-raw huggingface dataset:
The yeast cell according to claim 10 or 11, wherein the yeast cell is transformed with a nucleic acid molecule as defined in any of claims 1 to 5, and/or wherein the yeast cell is as defined in claim 6 or 7. 
Stanica kvasca u skladu s patentnim zahtjevom 10, naznačena time što se stanicu kvasca transformira molekulom nukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 1 do 5, i/ili što je stanica kvasca u skladu s patentnim zahtjevom 6 ili 7.
the at least two binding sites are genetically fused to the first and second Fc moiety, respectively, via an intervening amino acid sequence comprising a peptide linker, or 
najmanje dva mjesta vezanja genetički su fuzionirana s prvim odnosno drugim dijelom Fc, preko intervenirajućeg aminokiselinskog slijeda koji sadrži peptidnu spojnicu, ili
The precipitate was centrifugated down and then washed with deionized water until no Cl- was detectable (AgNO3). 
Talog je centrifugiran i tada opran s dcioniziranom vodom dok sc više nije CI detektirao (AgNO;).
The method of aspect 28, wherein the compound is selected from the group consisting of RD162', RD162", RD 169, or RD170, or a pharmaceutically acceptable salt thereof. 
FR GL Et (RDS: ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku liječenja hiper-proliferacijskog poremećaja, naznačen time, da je hiper-proliferativni poremećaj odabran iz skupine koja se sastoji od benigne hiperplazije prostate, karcinoma dojke, i karcinoma jajnika.
The double stranded RNAi agent of claim 1, wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand are modified nucleotides. 
Dvolančani RNAi agens u skladu s patentnim zahtjevom 1, naznačen time, da svi nukleotidi navedenog sens lanca i svi nukleotidi navedenog antisens lanca sadržavaju modifikaciju.
is hydrogen, unsubstituted or substituted C1-C20 alkyl, or unsubstituted or substituted aryl; and 
(11) Rg je vodik, nesupstituirani ili supstituirani C,-Czgalkil ili nesupstituirani ili supstituirani aril;
is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl; and 
je vodik, halogen, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani cikloalkenil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani heterocikloalkenil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani kondenzirani arilni prsten, ili supstituirani ili nesupstituirani heteroaril; i
EPMATHMARKEREP EPMATHMARKEREP The value of a for the material may then be calculated as the mean of all the measured values of a, e.g. of a1 and a2. 
-1x>n(PĆ) (PP) Vrijednost a za taj materijal se može tada izračunati kao srednja vrijednost svih izmjerenih veličina a, na primjer, a i
Specifically, the invention is directed to compounds of formula (I) 
Kombinacija, naznačena time što sadrži spoj formule (I):
Date of treatment start: 8.3.2010 
Datum podnošenja zahtjeva u HR:
The imaging material supply cartridge of claim 1, wherein the partition map identifies boundaries of data field groupings with data identifying a length of each of the data field groupings. 
Spremišna patrona za materijal za pisanje (24) u skladu s patentnim zahtjevom 1, naznačena time što particijska mapa (52) identificira granice grupacija podatkovnih polja podacima koji identificiraju duljine svake od grupacija podatkovnih polja.
The lighting module of claim 1, wherein said microchip is configured to regulate the energy that is delivered to said light emitting diode by adjusting the switching duty cycle of said switching device. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni mikročip konfiguriran da regulira energiju koja se isporučuje navedenoj LED diodi tako što prilagođuje preklopnu funkciju navedenog preklopnog sklopa.
Ar is a phenyl or heteroaryl; wherein the phenyl or heteroaryl is unsubstituted or substituted with one, two, or three R5 substituents; wherein each R5 substituent is independently selected from the group consisting of halogen, —C1-4alkyl, —OH, —OC1-4alkyl, —SC1-4alkyl, —CN, —CONRaRb, and —NO2; and wherein Ra and Rb are each independently —H or —C1-4alkyl; 
Ar je fenil ili heteroaril; pri čemu je fenil ili heteroaril nesupstituiran ili supstituiran s jednim, dva ili tri R5 supstituenta; pri čemu je svaki R5 supstituent neovisno odabran iz skupine koja sadrži halogen, -C1-4alkil, -OH, -OC1-4alkil, -SC1-4alkil, -CN, -CONRaRb i -NO2; i pri čemu Ra i Rb su svaki neovisno -H ili -C1-4alkil;
Rather, light scattering measurements reveal that the microaggregates have a variety of sizes falling within a distribution, and measurements can reveal a mean size. 
Štoviše, mjerenje raspršenim svijetlom otkriva da mikroagregati imaju raznolikost veličina koje padaju unutar distribucije, a mjerenja mogu otkriti srednju veličinu.
A compound selected from the group consisting of: 
Spoj prema zahtjevu 1 izabran iz grupe koja obuhvaća:
Compound of formula (I) according to claim 1, wherein the substituents of the pair (R1, R5) are identical and the substituents of the pair (R2, R4) are identical. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da su supstituenti para (R1, R5) te supstituenti para (R2, R4) istovjetni.
The powder formulation according to claim 10, wherein said process further comprises: further mixing said formulation obtained in (ii) to achieve an homogeneous distribution of the active ingredients. 
Formulacija praška prema patentnom zahtjevu 9, naznačeno time da rečeni postupak dalje obuhvaća: (iii) daljnje miješanje formulacije dobivene u (ii) da se postigne homogena distribucija aktivnih tvari.
An apparatus for mixing a material, wherein the apparatus comprises a mixing portion comprising a second container and the device as in claim 1; wherein the second container has a downstream outlet defining an opening and is sealably connected to the device around and proximal to the upstream apertures of the device in such a way that the device restricts the opening of the downstream outlet of the second container to the openings of the upstream apertures of the device; and the apparatus functions in such a way that when the mixing portion of the apparatus contains a material, the material can be discharged from the apparatus via the device without clogging the device. 
Postupak kao u zahtjevu 11, naznačen time, da koristi aparat za pre-disperziju i punjenje pre-disperzije u prvi spremnik, pri čemu je aparat učinkovit za miješanje materijala 1 pri čemu aparat podrazumijeva uređaj 1 dio za miješanje koji sadrži drugi spremnik; pri čemu drugi spremnik ima ispust nizvodno koji definira otvor i nepropusno je spojen oko i u blizini otvora uzvodno na uređaju na način da uređaj ograničava otvaranje ispusta nizvodno drugog spremnika prema otvorima uzvodno na uređaju; i aparat djeluje na takav način da se, kada drugi spremnik aparata sadrži materijal, materijal može biti ispušten 1z aparata putem uređaja bez začepljenja uređaja.
to 90 wt.-%, particularly 50 to 85 wt.-%, more preferably 65 to 80 wt.-% of mannitol; 
manitol od 30 do 90 masenih %, posebno od 50 do 85 masenih %, najbolje od 65 do 80 masenih %;
The isolated anti-Notch1 NRR antibody of claim 1, wherein said antibody binds the human Notch1 NRR and the mouse Notch1 NRR. 
Izolirano anti-Notch1-NRR-protutijelo prema zahtjevu 1, naznačeno time, da spomenuto protutijelo veže humani Notch1-NRR i mišji Notch1-NRR.
A polypeptide for use according to any one of claims 1-3, wherein said polypeptide is for use in the treatment of a congenital or acquired coagulopathy, a congenital or acquired haematological disease, a haemorrhagic disorder, or another cardiovascular disease. 
Polipeptid za uporabu, sukladno bilo kojem od zahtjeva 1-3, naznačen fime, da se navedeni polipeptid upotrebljava u liječenju kongenitalne ili stečene koagulopatije, urođene ili stečene hematološke bolesti, hemoragijskog poremećaja ili drugih kardiovaskularnih bolesti.
is selected from -CN, -OCF3, halogen, heteroaryl, optionally substituted with halogen or C1-3alkyl optionally substituted with halogen and phenyl, optionally substituted with halogen; 
R' je odabran od sljedećih: -CN, -OCF,, halogen, heteroaril opcijski supstituiran s halogenom ili C,salkil opcijski supstituiran s halogenom i fenil opcijski supstituiran s halogenom;
The compound for use according to claim 1 for use in the treatment of multiple sclerosis. 
Farmaceutski pripravak za uporabu prema zahtjevu 22, naznačen time, da imunološki poremećaj je reumatoidni artritis.
The antibody according to claim 1 or 2, wherein amino acid proline in position 331 in human IgG1 is changed to serine or another polar amino acid. 
Protutijelo prema zahtjevu 1 ili 2, pri čemu je aminokiselinski prolin na položaju 331 u humanom IgG1 promijenjen u serin ili drugu polarnu aminokiselinu.
An upper end face 27 of extension 25 abuts the curl 34 from below. 
Gornji kraj 27 produžetka 25 dolazi otprilike do zavijutka 34 s donje strane.
The salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid may be selected from the group consisting of the sodium salt, potassium salt and calcium salt of of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 
Kompozicija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što navedena sol N-(8-(2hidroksibenzoiljamino)kaprilne kiseline je natrijev N-(8-(2-hidroksibenzoil)amino)kaprilat (SNAC).
Display 112 will flash, "clean" during this mode. 
Displej 112 povremeno će bljeskanjem davati obavijest "čišćenje" ("clean") tijekom tog režima.
In one embodiment, the arginine is free L-arginine or a pharmaceutically acceptable salt of L-arginine. Preferably, the arginine has a purity of pharmaceutical grade or equivalent. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni L-arginin ili farmaceutski prihvatljiva sol od L-arginina.
the associator (252) is configured to sequentially associate the sequentially extracted first-type syntax elements to the positions of the transform coefficient block in a scan order among the positions of the transform coefficient block, which depends on the positions of the significant transform coefficients indicated by previously extracted and associated first-type syntax elements. 
Uređaj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je pridruživač (252) konfiguriran tako, da predodređeni red skeniranja ovisi od pozicija signifikantnih koeficijenata transformacije koji su prikazani putem prethodno izvučenih i pridruženih elemenata sintakse prvog tipa.
The pharmaceutically effective carrier may be solid or liquid. 
Farmaceutski prihvatljiv nosač može biti kruti ili tekući.
The compound or salt for use according to claim 9, wherein said additional pharmaceutical agent is a corticosteroid. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak rak glave i vrata.
The reason for this is that concentrations less than 10−10 M cannot be measured sufficiently reliably by the current analytical methods. Thus, according to one aspect, the present invention relates to a process for preparing a liquid pharmaceutical formulation of complex of macrocyclic chelate with lanthanide, the said process comprising at least one step of measuring in the liquid pharmaceutical formulation concentrations of free macrocyclic chelate (Cch 1) and/or of free lanthanide (Clan 1) and at least one step of adjusting the Cch 1 and/or the Clan 1, so as to obtain (sufficiently stably in the final pharmaceutical solution, i.e. the pharmaceutical formulation intended to be administered to the patient) a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%. 
HR P20161312 T1 PATENTNI ZAHTJEVI Postupak za pripravu tekuće farmaceutske formulacije koja sadrži kompleks makrocikličkog kelata s lantanidom i mol/mol količinu slobodnog makrocikličkog kelata između 0.002% i 0.4%, te navedeni postupak sadrži sljedeće uzastopne korake: b) pripravu tekućeg farmaceutskog pripravka koji sadrži kompleks makrocikličkog kelata s lantanidom, te slobodni makrociklički kelat koji nije u obliku pomoćne tvari X[X',L] gdje L je makrociklički kelat i X i X' su metalni ion, naročito odabran neovisno od kalcija, natrija, cinka i magnezija, i/ili slobodnog lantanida, pomoću miješanja otopine slobodnog DOTA kao slobodnog makrocikličkog kelata 1 slobodnog gadolinija kao slobodnog lantanida, tako da se dobije kompleksirani lantanid pomoću makrocikličkog kelata,količine slobodnog makrocikličkog kelata 1 slobodnog lantanida su takve da se sav lantanid kompleksira 1 da Cal > Ceca
Preferably, the amount of riluzole or said pharmaceutically acceptable salt or derivative thereof is from about 0.1% to about 20% w/v. In a more preferred embodiment, riluzole is present in amounts from about 0.2% to about 10% w/v, preferably from about 0.3 to about 6% w/v. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što riluzol ili navedena njegova farmaceutska sol dolaze u količinama od 0,1% do 20% tež./vol., po mogućnosti od 0.2% do 10% tež./vol., poželjnije od 0,3% do 6% tež./vol.
MIII is a transition metal of group IIIA, or group 13 in the IUPAC nomenclature, 
M" je prijelazni metal iz skupine III, ili skupine 13 u IUPAC-ovoj nomenklaturi,
the antibody or antigen binding portion thereof is administered in combination with a second therapeutic agent, wherein the second therapeutic agent is (a) a second anti-cancer antibody; or (b) an anti-cancer small molecule. 
(b) antitijelo ili njegov dio koji se vezuje za antigen je primjenjeno u kombinaciji s drugim terapijskim sredstvom, pri čemu je drugo terapijsko sredstvo drugo antitijelo ili njegov dio koji se vezuje za antigen ili drugo sredstvo protiv karcinoma.
Eur J Pain. 2007; 11(6):605-613 . A pharmaceutical composition comprising baclofen and D-sorbitol, or salts thereof, for use in the treatment of Charcot-Marie Tooth disease (CMT), or a related disorder selected from Dejerine-Sottas syndrome (DSS) and congenital hypomyelinating neuropathy (CHN). 
Smjesa koja sadrži barem dva spoja izabrana između D-sorbitola; baklofena; pilokarpina; naltreksona; metimazola; mifepristona, i ketoprofena ili njihovih soli, za istodobnu, zasebnu ili sekvencijsku primjenu za uporabu u liječenju Charcot-Marie Tooth (CMT) bolesti, ili srodnog poremećaja izabranog između nasljedne neuropatije sa sklonošću kljenuti na pritisak (HNPP), Dejerine-Sottas sindroma (DSS) i kongenitalne hipomijelinizirajuće neuropatije (CHN).
In the treatment of urinary incontinence, the hydrogel is typically injected into the urethra, specifically under the submucosal membrane of the urethra. 
Kod liječenja urinarne inkontinencije tipično je da se hidrogel injektira u mokraćnu cijev, naročito ispod submukozne membrane mokraćne cijevi.
A salt of a compound of formula III according to claim 4, wherein the salt is formed by methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-a-methyl-benzylamine or N-methyl-D-glucosamine. 
Sol spoja formule Ill prema zahtjevu 4, naznačena time, da je sol stvorena od metilamina, dietanolamina, etanolamina, magnezij-sulfata, L-lizina, benzilamina, L(-)-a-metil-benzilamina ili N-metil-D-glukozamina.
A system according to claim 26, 27 or 28, wherein the generator comprises a data recorder, for recording the collection of secret codes on a non-volatile data support (50). 
Sistem u skladu s patentnim zahtjevom 26, 27 ili 28, naznačen time, da navedeni generator sadrži snimač podataka za snimanje zbirke tajnih kodova na nosaču podataka (50) postojane memorije.
A conjugated nucleic acid molecule which has one of the following formulae: wherein the underlined nucleotide refers to a nucleotide having or not having a phosphorothioate or methylphosphonate backbone, the linked L' is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4) and 2,19-bis(phosphor)-8-hydraza-1-hydroxy-4-oxa-9-oxo-nonadecane; m is 1, L is a carboxamido oligoethylene glycol and C is selected from the group consisting of dioleoyl, octadecyl, folic acid, tocopherol and cholesterol. 
ia pas pena >L OGATOCAGACAAACCACOCAA ACGTOCOACIGTG_ (Ile), gdje se podcrtani nukleotid odnosi na nukleotid koji ima ili koji nema fosforotioatnu ili metilfosfonatnu okosnicu, vezani L' se bira iz skupine koju čine heksaetilen-glikol, tetradeoksitimidilat (T4) 1 2,19-bis(fosfor)-8-hidraza-1- hidroksi-4-oksa-9-oksononadekan; m je 1, L je karboksamidooligoetilen-glikol, a C se bira iz skupine koju čine dioleo1l, oktadecil, folna kiselina, tokoferol i kolesterol.
The monoclonal antibody according to item 1, wherein the antibody comprises: a heavy chain amino acid sequence that is at least 90% identical to the heavy chain amino acid sequence of antibody Bax8, antibody Bax69, antibody Bax74, antibody Bax94, antibody Bax152 and antibody BaxA10; 
C) Vi sekvencu koja je najmanje 90% identična aminokiselinskoj sekvenci jakog lanca od protutijela Bax69, protutijela Bax94, protutijela Bax152 i protutijela BaxA10, sva kao što su gore definirana, d) VL sekvencu koja je najmanje 90% identična aminokiselinskoj sekvenci slabog lanca od protutijela Bax69, protutijela Bax94, protutijela Bax152 i protutijela BaxA10, sva kao što su gore definirana,
New York, or from compounds XI using the methods of Arnould et al. Tetrahedron Lett. 
Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John Wiley & Sons, Inc., New York, ili iz spojeva XI na način opisan u Arnould i sur.
Examples of conventional apparatuses are, e.g., ultrasound scalers for removal of tartar within dentistry. 
Primjeri konvencionalnih aparata su npr. ultrazvučna sonda za uklanjanje zubnog kamenca u zubarstvu.
The compound according to item 1, wherein two R10 units are be taken together to form a substituted or unsubstituted C2-C8 heterocyclic ring, wherein the heterocyclic ring comprises one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S). 
C& Or Cig, supstituirani ili nesupstituirani C>-Cg heterociklični prsten, ili supstituirani ili nesupstituirani C3z do Cs5 heteroaril prsten, pri čemu heterociklični 1 heteroarilni prsteni obuhvaćaju jedan ili više hetero atoma neovisno odabranih između kisika (O), dušika (N), ili sumpora (S).
The hypolipidemic agent may be an up-regulator of LD2 receptor activity, such as MD-700 (Taisho Pharmaceutical Co. 
Hipolipidemijsko sredstvo može biti ushodni regulator LD2 receptorne aktivnosti, kao što je MD-700 (Taisho Pharmaceutical Co.
A method for treating a bone-related disorder in a mammalian subject which comprises providing to a subject in need of such treatment a pharmaceutical composition according to any one of claims 28, 29 or 30. The method according to claim 37, wherein the bone-related disorder is at least one of primary and secondary osteoporosis, osteopenia, osteomalacia, osteogenesis imperfecta (OI), avascular necrosis (osteonecrosis), fractures and implant healing (dental implants and hip implants), bone loss due to other disorders such as bone loss associated with HIV infection, cancers, or arthritis. 
Protutijelo prema bilo kojem od zahtjeva 1 do 4, ili farmaceutski sastav prema bilo kojem od zahtjeva 8 do 11, naznačen(0) time, da se upotrebljava za liječenje ili profilaksu patološkog poremećaja koji je posredovan sklerostinom ili je povezan s povećanjem razine sklerostina, pri čemu je patološki poremećaj barem jedan od sljedećih: primarna i sekundarna osteoporoza, osteopenija, osteomalacija, osteogenesis imperfecta, vaskularna nekroza također poznata pod nazivom osteonekroza, frakture i zacjeljivanje implantatima uključujući dentalne implantate i implantate za kuk, gubitak kostiju zbog ostalih poremećaja kao što je gubitak kostiju povezan s HIV - infekcijom, rakom ili artritisom.
The flange ring 70 is preferably provided with a ring section 72 that rests on the base body 20 in the axial direction and extends through the opening 45 in the covering element 40 —as shown in FIG. 
Å titnik prema patentnom zahtjevu 7 ili 8, okarakteriziran time da je u osnovnom tijelu (20) postavljen prsten (80) za zaključavanje, gdje je prirubni prsten (70) fiksiran na prsten (80) za zaključavanje.
Aflibercept for use in treating a patient according to any one of claims 1 to 7 and 9 to 12, wherein folinic acid at a dosage of 400 mg/m2, 5-fluorouracil (5-FU) at a dosage of 2800 mg/m2, irinotecan at a dosage of 180 mg/m2 and aflibercept at a dosage of 4 mg/kg are administered to patient. 
Aflibercept za uporabu u liječenju pacijenta prema bilo kojem od patentnih zahtjeva 1 do 7 19 do 12, naznačen time što se pacijentu daju folinska kiselina u dozi od 400 mg/m', 5-fluorouracil (5-FU) u dozi od 2800 mg/m', irinotekan u dozi od 180 mg/m' i aflibercept u dozi od 4 mg/kg.
A vector comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 3 and a nucleic acid encoding the amino acid sequence of SEQ ID NO: 4. 
4. Vektor naznačen time da sadrži nukleinsku kiselinu koja enkodira aminokiselinsku sekvencu SEQ ID NO: 31 nukleinsku kiselinu koja enkodira aminokiselinsku sekvencu SEQ ID NO: 4.
The pharmaceutical composition according to claim 1, further comprising at least one additional peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO 3 to SEQ ID NO 20. 
Farmaceutski sastav prema zahtjevu 1, koji nadalje uključuje najmanje jedan dodatni peptid koji sadrži slijed aminokiselina odabranog iz skupine koja se sastoji od SEQ ID NO 1 te SEQID NO 4 do SEQ ID NO 12.
The system according to any preceding claim, wherein the frame comprises an opening for allowing introduction of the deposit into the interior space and a closure member for closing the opening. 
Sustav u skladu sa svakim od prethodnih zahtjeva, naznačen time što okvir sadrži otvor (332) koji omogućava uvođenje umetka u unutrašnji prostor, kao i zatvarač (330), za zatvaranje otvora.
Add 5 kg of 70% ethanol solution mix and cover. 
Dodati 5 kg smjese 70% etanolske otopine i pokriti.
Harvested cysts according to claim 24, wherein said transition metal is Fe2O3 (hematite or magnemite) or MnO2 (manganese dioxide). 
(hematit ili magnemit), MnO, (manganov dioksid) ili ferit, poželjno Fe:O, (magnetit).
Pharmaceutical composition according to item 15 containing dimethylfumarate at a dose range of 250 mg to 375 mg and teriflunomide at a dose range of 0.5 mg to 3 mg or fingolimod at a dose range of 0.025 mg to 0.20 mg or laquinimod ar a dose range of 0.025 mg to 0.125 mg. 
Kombinacija za uporabu prema zahtjevu 16. naznačena time što sadrži dimetilfumarat u rasponu doze od 250 mg do 375 mg i teriflunomid u rasponu doze od 0,5 mg do 3 mg ili fingolimod u rasponu doze od 0,025 mg do 0,20 mg.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline dioxalate salt of claim 1, in micronized form. 
Farmaceutski sastav koji sadrži farmaceutski prihvatljiv nosač i spoj prema zahtjevu 16.
The explosion proof and environment protective oil refueling equipment of any one of Claims 1-9, characterized in that the unit is covered with a metal protective mesh. 
Oprema za nadolijevanje nafte koja je otporna na eksploziju i štiti okoliš prema zahtjevu 2, naznačena time da je jedinica prekrivena s metalnom zaštitnom mrežom (W).
Evaporation of the solvent followed by washing 3 times with light petroleum and drying in vacuum gave a white crystalline powder of tetra-omeprazold titanium salt, mp >260°C. 
Uparavanje otapala i zatim pranje 3 puta s lakim petrolejom 1 sušenjem u vakuumu daje kristalni prah tetraomeprazol titanij soli 1.t. > 260 *C.
The method of claim 1, further comprising the step of adding water to the carbonylation product stream before it enters the second reaction zone. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje korak dodavanja vode u struju produkta karboniliranja prije nego uđe u drugo područje reakcije.